← Agios Pharmaceuticals, Inc. (AGIO) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Agios Pharmaceuticals, Inc. (AGIO)
Pharmaceutical Preparations · market cap $2.1B · as of 2026-07-16
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-10-29 (est.)
Earnings
Pipeline
3
programs
Upcoming events
2
next 90d+
Dossier
Ready
cached
Agios Pharmaceuticals (AGIO) is a Cambridge, MA-based rare disease biotech with 536 employees and a ~$2.4B market cap, focused on hemolytic anemias. Its lead asset mitapivat is in Phase 3 for Sickle Cell Disease, with AG-348 (also mitapivat, branded) in Phase 3 for Pyruvate Kinase Deficiency and tebapivat in Phase 2 for Myelodysplastic Syndromes. The company carries a critical financial constraint: $113.6M cash against a reported 2.9-month runway, making near-term capital markets activity a near-certainty.
The catalyst path
- 2026-10-29 (est.)Earningsimp 5/10
- 2026-11-01PDUFAimp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Tebapivat | Phase 2 | Myelodysplastic Syndromes |
| Mitapivat | Phase 3 | Sickle Cell Disease |
| AG-348 | Phase 3 | Pyruvate Kinase Deficiency |
Price & technical context
3-month
-10.3%
6-month
-1.7%
12-month
-17.2%
52-wk range
$22.34–$45.49
vs 50-day MA
-1.0%
vs 200-day MA
+7.4%
Realized vol
103.9%
Max drawdown
-63.8%
Daily closes through 2026-09-30. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for AGIO (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 3 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.